Cell Therapy News/Articles, page-16993

A lot of research going on in the stem cell space but no license deals for Mesoblast yet ? Time to sell some licenses me thinks


https://www.stemcell.com/psc-cell-q...psc_cellquality_standards&utm_content=ssn


ISSCR Standards for Human Stem Cell Use in Research


Recently, the International Society for Stem Cell Research (ISSCR) released the Standards for Human Stem Cell Use in Research, a document that outlines a set of recommendations that establish the minimum characterization and reporting criteria for working with human stem cells. These five tenets of responsible research practices can be used to shape the future of human stem cell research, leading to higher quality results and more standardized practices.

Discover how STEMCELL can support you in following these guidelines by exploring the resources below, and check back regularly to this page for updated content.








https://www.nature.com/articles/s41375-023-02039-z

An “off-the-shelf” CD2 universal CAR-T therapy for T-cell malignancies


Abstract

T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden the use of CAR-T cells in pan T-cell malignancies, we developed an allogeneic “universal” CD2-targeting CAR-T cell (UCART2), in which the CD2 antigen is deleted to prevent fratricide, and the T-cell receptor is removed to prevent GvHD. UCART2 demonstrated efficacy against T-ALL and CTCL and prolonged the survival of tumor-engrafted NSG mice in vivo.

To evaluate the impact of CD2 on CAR-T function, we generated CD19 CAR-T cells (UCART19) with or without CD2 deletion, single-cell secretome analysis revealed that CD2 deletion in UCART19 reduced frequencies of the effector cytokines (Granzyme-B and IFN-γ. We also observed that UCART19ΔCD2 had reduced anti-tumor efficacy compared to UCART19 in a CD19+NALM6 xenograft model. Of note is that the reduced efficacy resulting from CD2 deletion was reversed when combined with rhIL-7-hyFc, a long-acting recombinant human interleukin-7. Treatment with rhIL-7-hyFc prolonged UCART2 persistence and increased survival in both the tumor re-challenge model and primary patient T-ALL model in vivo. Together, these data suggest that allogeneic fratricide-resistant UCART2, in combination with rhIL-7-hyFc, could be a suitable approach for treating T-cell malignancies.